Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

Mano, 2008, Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer, Cancer Sci, 99, 2349, 10.1111/j.1349-7006.2008.00972.x

Palmer, 2009, Anaplastic lymphoma kinase: signalling in development and disease, Biochem J, 420, 345, 10.1042/BJ20090387

Pulford, 2004, Anaplastic lymphoma kinase proteins in growth control and cancer, J Cell Physiol, 199, 330, 10.1002/jcp.10472

Soda, 2007, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature, 448, 561, 10.1038/nature05945

Rikova, 2007, Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer, Cell, 131, 1190, 10.1016/j.cell.2007.11.025

Solomon, 2009, ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer, J Thorac Oncol, 4, 1450, 10.1097/JTO.0b013e3181c4dedb

Weickhardt, 2011, The therapeutic potential of anaplastic lymphoma kinase inhibitors in lung cancer: rationale and clinical evidence, Clin Invest, 1, 1119, 10.4155/cli.11.92

Choi, 2008, Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer, Cancer Res, 68, 4971, 10.1158/0008-5472.CAN-07-6158

Takeuchi, 2009, KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer, Clin Cancer Res, 15, 3143, 10.1158/1078-0432.CCR-08-3248

Butrynski, 2010, Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor, N Engl J Med, 363, 1727, 10.1056/NEJMoa1007056

Camidge, 2010, Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment, Clin Cancer Res, 16, 5581, 10.1158/1078-0432.CCR-10-0851

Shaw, 2009, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK, J Clin Oncol, 27, 4247, 10.1200/JCO.2009.22.6993

Takahashi, 2010, Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene, Ann Surg Oncol, 17, 889, 10.1245/s10434-009-0808-7

Wong, 2009, The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS, Cancer, 115, 1723, 10.1002/cncr.24181

Zhang, 2010, Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression, Mol Cancer, 9, 188, 10.1186/1476-4598-9-188

Varella-Garcia, 2010, ALK gene rearrangement in unselected Caucasians with non-small cell lung cancer (NSCLC), Proc Am Soc Clin Oncol, 28

Kris, 2011, Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI's Lung Cancer Mutation Consortium (LCMC), Proc Am Soc Clin Oncol, 29

Christensen, 2007, Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma, Mol Cancer Ther, 6, 3314, 10.1158/1535-7163.MCT-07-0365

Zou, 2007, An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms, Cancer Res, 67, 4408, 10.1158/0008-5472.CAN-06-4443

Kwak, 2009, Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066, Proc Am Soc Clin Oncol, 7

Kwak, 2010, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer, N Engl J Med, 363, 1693, 10.1056/NEJMoa1006448

Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205

Camidge, 2010, Clinical activity of crizotinib (PF-02341066), in ALK-positive patients with non-small cell lung cancer (NSCLC), Ann Oncol, 21

Ou, 2010, Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer, J Thorac Oncol, 5, 2044, 10.1097/JTO.0b013e318200f9ff

Scagliotti, 2009, The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies, Oncologist, 14, 253, 10.1634/theoncologist.2008-0232

Schiller, 2002, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer, N Engl J Med, 346, 92, 10.1056/NEJMoa011954

Doebele, 2012, Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer, Cancer, 10.1002/cncr.27409

Ou SI, Salgia R, Clark J, et al. Comparison of crizotinib (PF-02341066) pharmacokinetics between Asian and non-Asian patients with advanced malignancies. 4th Asia Pacific Lung Cancer Conference (APLCC), Seoul, South Korea, Dec 2–4, 2010. Oral presentation O35.

Rosell, 2009, Screening for epidermal growth factor receptor mutations in lung cancer, N Engl J Med, 361, 958, 10.1056/NEJMoa0904554

Camidge, 2011, Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed, J Thorac Oncol, 6, 774, 10.1097/JTO.0b013e31820cf053

Lee, 2011, Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer, J Thorac Oncol, 6, 1474, 10.1097/JTO.0b013e3182208fc2

Mehra, 2012, First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors, Proc Am Soc Clin Oncol, 30

Sequist, 2010, Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer, J Clin Oncol, 28, 4953, 10.1200/JCO.2010.30.8338

Lee, 2012, Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer, Cancer, 118, 3579, 10.1002/cncr.26668

Kim, 2012, Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement, Cancer, 118, 729, 10.1002/cncr.26311

Shaw, 2011, Effect of crizotinib on overall survival in advanced NSCLC harboring anaplastic lymphoma kinase gene rearrangement: a retrospective analysis, Lancet Oncol, 11, 1004, 10.1016/S1470-2045(11)70232-7

Spigel, 2011, Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC, Proc Am Soc Clin Oncol, 29

Costa, 2011, CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib, J Clin Oncol, 29, e443, 10.1200/JCO.2010.34.1313

Engelman, 2008, Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer, Clin Cancer Res, 14, 2895, 10.1158/1078-0432.CCR-07-2248

Choi, 2010, EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors, N Engl J Med, 363, 1734, 10.1056/NEJMoa1007478

Sasaki, 2011, A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors, Cancer Res, 71, 6051, 10.1158/0008-5472.CAN-11-1340

Doebele, 2012, Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer, Clin Cancer Res, 18, 1472, 10.1158/1078-0432.CCR-11-2906

Katayama, 2012, Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers, Sci Transl Med, 4, 120ra17, 10.1126/scitranslmed.3003316

Chaft, 2011, Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design, Clin Cancer Res, 17, 6298, 10.1158/1078-0432.CCR-11-1468

Crinò, 2011, Initial phase 2 results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005, Proc Am Soc Clin Oncol, 29